ISRCTN79261738已完成未知
The antiretroviral roll out for human immunodeficiency virus (HIV) in India (HIVIND) - strengthening capacity to promote adherence and patient follow-up in the context: a two-centre, randomised, controlled, open trial in South India to study an innovative approach using mobile phones delivery to promote adherence in antiretroviral naive, HIV+ Indian patients
European Union (EU) (Belgium)0 个研究点目标入组 600 人开始时间: 2009年7月24日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Human immunodeficiency virus (HIV) seropositive
- •2. Aged between 18 - 60 years, either sex
- •3. Meet criteria to start ART (in India, ART is indicated for symptomatic patients with a World Health Organization [WHO] Clinical Stage 4 condition regardless of CD4 counts and plasma viral load; WHO Stage 3 condition with CD4 less than 350/mm^3 and in asymptomatic patients, with CD4 count less than 200/mm^3)
- •4. ART naive (i.e. no prior antiretroviral therapy or ART for less than 7 days)
- •5. Residence in the Southern Indian States with the ability to visit clinic regularly for follow-up visits
排除标准
- •1. Severely ill (Karnofsky score less than 70) at the time of recruitment
- •2. Impaired renal function (creatinine greater than 2 times upper limit of normal)
- •3. Study participant already recruited in the same household
- •4. Non-availability of mobile telephone network
研究者
相似试验
已完成
不适用
Directly Observed antiretroviral Therapy for people living with Human Immunodeficiency Virus (HIV) and Acquired ImmunDeficiency Syndrome (AIDS): a randomised controlled trialISRCTN48682427Ministry of Health (Brazil)
进行中（未招募）
1 期
Initiation of first-line antiretroviral treatment with TENOFOVIR ALAFENAMIDE - EMTRICITABINE - BICTEGRAVIR at the first clinical contact in France: Trial IMEA 055 – FASTHIV positive age > 18 years -newly diagnosed HIV-infected individual evidenced by any tests -antiretroviral-treatment naive -negative urine pregnancy test -willing to sign an informed written consent– -regular health insurance -willing to provide two distinct contact information (telephone number and/or email) in order to be easily reached if needed between Day 0 and Day 7EUCTR2019-000812-27-FRIMEA110
尚未招募
不适用
To check the occurrence of Human Immunodeficiency Virus (HIV) among Indian Men who have Sex with Men(MSM)CTRI/2022/09/045982Department of Health Research
已完成
不适用
Highly active anti-retroviral therapy including nevirapine once daily versus twice daily after at least 12 weeks of nevirapine twice daily. A randomized, open, multicentre trial.ISRCTN81305260Institute of Biomedical Investigations of Bellvitge (Institut d'Investigació Biomèdica de Bellvitge) (IDIBELL) (Spain)308
招募中
不适用
igeria PrEP Demonstration StudyHIV/AIDSPACTR201605001602542ational Agency for the Control of AIDS600